南新制药：预计2025年年度净利润-1.6亿元到-1.2亿元

Group 1 - The company Nanjing New Pharmaceutical is expected to report a net loss attributable to shareholders of the parent company for the year 2025, estimated between -160 million to -120 million yuan [1] - Compared to the same period last year, the loss is expected to decrease by approximately 197 million to 237 million yuan, representing a year-on-year reduction of 55.17% to 66.38% [1] - The main reasons for the performance change include intensified market competition due to domestic pharmaceutical industry procurement policies and the continuous launch of similar competing products, as well as a decrease in operating income and gross margin due to fewer flu cases in the first three quarters of 2025 [1] Group 2 - The company has maintained a high level of research and development investment to sustain its core competitiveness despite the reported losses [1] - During the reporting period, the company prudently recognized asset impairment losses and credit impairment losses [1]